Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Receivables (2024 - 2025)

Caris Life Sciences has reported Receivables over the past 2 years, most recently at $119.3 million for Q4 2025.

  • Quarterly results put Receivables at $119.3 million for Q4 2025, up 28.54% from a year ago — trailing twelve months through Dec 2025 was $119.3 million (up 28.54% YoY), and the annual figure for FY2025 was $119.3 million, up 28.54%.
  • Receivables for Q4 2025 was $119.3 million at Caris Life Sciences, up from $36.6 million in the prior quarter.
  • Over the last five years, Receivables for CAI hit a ceiling of $119.3 million in Q4 2025 and a floor of $36.6 million in Q3 2025.